Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China.

Front Immunol · 2021 · PMC8789657 · PMID 35095833

Europe PMC DOI

hedged sentence

0.0790

closest p · 1.6× alpha

0.0790

boldest claim

The sentences

showed a trendP = 0.079so close (0.05 < p ≤ 0.1)

Interestingly, when toripalimab was administrated two days after chemotherapy rather than being used simultaneously, the combinational neoadjuvant regime showed a trend toward a higher pCR rate (36.4%, 4/11 versus 7.7%, 1/13, P = 0.079) ( 60 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.